Spinar J, Novotný J, Mayer J, Vítovec J, Spinarová L
II. interní klinika, FN Brno.
Vnitr Lek. 1995 Jan;41(1):3-7.
Chronic congestive heart failure is one of the risk groups of acquired hypercoagulant and hyperviscous state. In a group of patients with medium and severe cardiac failure the administration of sulodexide led to an increased activation of the fibrinolytic potential--a drop of PAI-1 and fibrinogen, to an increased activation of anticoagulatory potential--an increase of AT III and reduced plasma viscosity. Global coagulation and biochemical screening parameters were not affected by treatment. Administration of the preparation did not exert important undesirable effects and was well tolerated.
慢性充血性心力衰竭是获得性高凝和高黏状态的风险群体之一。在一组中重度心力衰竭患者中，使用舒洛地特可导致纤溶潜能激活增加——PAI-1和纤维蛋白原水平下降，抗凝潜能激活增加——AT III水平升高且血浆黏度降低。整体凝血和生化筛查参数不受治疗影响。该制剂的使用未产生重要的不良影响，且耐受性良好。
